Avalon Ventures and COI Pharmaceuticals announce acquisition of Sitari Pharmaceuticals by GSK

This article was originally published here

Sitari has been developing a novel treatment for celiac disease and was the first company formed under the GSK-Avalon venture collaboration in 2013. Sitari was incubated at COI

The post Avalon Ventures and COI Pharmaceuticals announce acquisition of Sitari Pharmaceuticals by GSK appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply